Abstract:
This study delves into the investigation of Schisandrin-A's antibacterial efficacy against
Enterococcus faecalis jh2-2, a pathogenic strain associated with escalating concerns of
antibiotic resistance. Recognizing the pressing need for alternative treatments, we
employed a multifaceted approach, including Minimum Inhibitory Concentration (MIC)
testing, DNA extraction, Time-Kill Kinetics assays, and Scanning Electron Microscopy.
Through meticulous MIC testing, concentration-dependent antibacterial effects of
Schisandrin-A were revealed, showcasing its potential as a potent agent against
Enterococcus faecalis. Drug DNA interaction techniques provided insights into the
molecular dynamics of the compound's interaction, unraveling potential structural
changes and binding modes with bacterial DNA. The Time-Kill Kinetics assays further
elucidated the bactericidal activity of Schisandrin-A over varying concentrations and time
intervals. These assays offered a comprehensive understanding of the compound's impact
on bacterial viability, providing valuable data for assessing its therapeutic potential.
Scanning Electron Microscopy unveiled morphological changes induced by SchisandrinA, shedding light on its mechanisms of action at a microscopic level. These findings
collectively contribute to a nuanced comprehension of Schisandrin-A's antibacterial
effects, offering insights into its potential application in combating antibiotic-resistant
strains, particularly Enterococcus faecalis jh2-2. This research holds significant
implications for public health, addressing the challenges posed by antibiotic-resistant
bacterial strains. The identified antibacterial properties of Schisandrin-A provide a
foundation for further exploration and development of alternative therapeutic strategies,
aiming to mitigate the risks associated with conventional antibiotic treatments. Byvii
unraveling the complex interplay between Schisandrin-A and Enterococcus faecalis jh2-
2, this study contributes to the ongoing efforts to confront the global issue of antibiotic
resistance and enhance the arsenal of effective antibacterial agents.
